The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusion/rearrangement or wild-type (WT) FGFR2.
 
Rachna T. Shroff
Consulting or Advisory Role - Agios; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Debiopharm Group; Exelixis; Incyte; Merck; QED Therapeutics; Taiho Pharmaceutical
Research Funding - Exelixis; Halozyme; Merck; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Taiho Pharmaceutical
 
Jessica Rearden
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
 
Ai Li
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
 
Susan Moran
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
 
Stacie Peacock Shepherd
Employment - Corcept Therapeutics; QED Therapeutics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; BridgeBio Pharma; Calithera Biosciences; Corcept Therapeutics
Patents, Royalties, Other Intellectual Property - Patents pending for Corcept Therapeutics
 
Angela Lamarca
Consulting or Advisory Role - Eisai; Ipsen; Nutricia; Nutricia (I); QED Therapeutics; Roche
Speakers' Bureau - Advanced Accelerator Applications; Incyte; Ipsen; Ipsen (I); Merck; Novartis (I); Pfizer; Pfizer (I)
Research Funding - Ipsen; Ipsen (I); Roche
Travel, Accommodations, Expenses - Abbott Nutrition; Advanced Accelerator Applications; Bayer; Celgene; Delcath Systems; Ipsen; Ipsen (I); Mylan; NanoString Technologies (I); Novartis; Pfizer; Sirtex Medical